12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $5.3B | $287M | 87.5% | 8.4% | $942M | $845M | $4.5B |
| 2024 | $3.8B | -$645M | 84.4% | -14.9% | -$633M | $1.9B | $2.6B |
| 2023 | $2.5B | -$882M | 84.5% | -49.1% | -$1.7B | $886M | $3.2B |
| 2022 | $1.4B | -$2.0B | 79.8% | -126.4% | -$1.8B | $538M | $3.9B |
| 2021 | $1.2B | -$1.5B | 86.0% | -122.3% | -$1.6B | $630M | $4.4B |
| 2020 | $309M | -$1.6B | 77.1% | -536.7% | -$1.4B | $854M | $1.4B |
| 2019 | $428M | -$949M | 83.4% | -224.2% | -$840M | $83M | $618M |
| 2018 | $198M | -$674M | 85.5% | -356.1% | -$618M | $50M | $713M |
| 2017 | $238M | -$93M | 97.9% | -41.3% | -$34M | $18M | $240M |
| 2016 | $1M | -$119M | 100.0% | -10940.2% | -$113M | $17M | $88M |
| 2015 | — | -$57M | — | — | -$45M | — | $18M |
| 2014 | — | -$18M | — | — | — | — | $14M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1.5B | $227M | 89.0% | 16.5% | $161M | $852M | $4.8B |
| Dec '25 | $1.5B | $67M | 90.5% | 12.4% | $380M | $845M | $4.5B |
| Sep '25 | $1.4B | $125M | 86.1% | 11.5% | $354M | — | $4.0B |
| Jun '25 | $1.3B | $94M | 87.5% | 6.7% | $220M | $954M | $2.8B |
| Mar '25 | $1.1B | $1M | 85.2% | 1.0% | -$12M | $924M | $2.5B |
| Dec '24 | $1.1B | -$152M | 85.8% | -7.0% | -$17M | $1.9B | $2.6B |
| Sep '24 | $1.0B | -$121M | 83.0% | -12.0% | $55M | $1.1B | $2.7B |
| Jun '24 | $929M | -$120M | 85.1% | -11.5% | -$206M | $1.0B | $2.6B |
| Mar '24 | $752M | -$251M | 83.4% | -34.8% | -$465M | $1.0B | $2.8B |
| Dec '23 | $634M | -$368M | 83.3% | -60.5% | -$379M | $886M | $3.2B |
| Sep '23 | $781M | $215M | 87.7% | -17.1% | -$236M | $531M | $3.1B |
| Jun '23 | $595M | -$381M | 83.9% | -53.5% | -$415M | $628M | $3.4B |
| Mar '23 | $448M | -$348M | 81.7% | -82.9% | -$689M | $488M | $3.5B |
| Dec '22 | $380M | -$445M | 80.7% | -123.3% | -$440M | $538M | $3.9B |
| Sep '22 | $388M | -$558M | 80.3% | -113.1% | -$671M | $649M | $4.2B |
| Jun '22 | $342M | -$566M | 79.2% | -128.6% | -$430M | $566M | $4.5B |
| Mar '22 | $307M | -$435M | 78.7% | -144.6% | -$282M | $609M | $4.3B |
| Dec '21 | $214M | -$591M | 77.3% | -267.2% | -$623M | $630M | $4.4B |
| Sep '21 | $206M | -$438M | 77.0% | -224.0% | -$563M | $643M | $1.4B |
| Jun '21 | $150M | -$480M | 75.8% | -316.6% | -$459M | $630M | $1.8B |
How the market has priced ONC against its own fundamentals since 2025-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Beone Medicines Ltd.'s revenue has grown 76.8% per year. These are computed facts, not advice.
As of FY2025, Beone Medicines Ltd. reported $845M of total debt against $4.5B of cash; operating income covered interest expense 7.7×.
In FY2025, gross margin was 87.5%, operating margin 8.4%, and net margin 5.4%.
As of Jun '26, Beone Medicines Ltd. traded at a price-to-earnings ratio of about 1387.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.